Posts tagged ‘Pharma Consultant’
Pieter Droppert has prepared a short (2 minute) video review of BIO 2011, in which he notes that one of the major themes of the meeting was facilitating partnering, licensing & business development discussions between pharmaceutical and biotechnology companies.
Astra Zeneca tweeted that they had 500 partnering discussions planned, a number that is perhaps not so surprising in light of their pipeline and patent cliff over the next few years.
Another major focus of BIO was the marketing of biotechnology regions that takes place in the exhibit hall and at satellite events. Pieter has written in more detail on Biotech Strategy Blog about the session on innovation he attended, networking opportunities and the face of biotech social media.
His not too serious BIO 2011 video, that you can watch below, captures what he thought of the meeting as a first-time attendee.
We wish our Canadian clients a Happy Canada Day today and our United States clients an enjoyable Independence Day weekend. Icarus Consultants will be open for business again on Tuesday, July 5th.
Have you noticed that when you search for something on the web, the results now frequently contain videos to watch?
We at Icarus Consultants believe this trend towards video based information is set to continue.
It is perhaps not surprising given that anyone can easily shoot video on a home computer or iphone. Storytelling using video and audio is simply more engaging than just reading.
I don’t think it will be too long before we see more pharma/biotech companies with their own channels on YouTube and other social media platforms. The advantage of video is that once it has been uploaded to YouTube or Vimeo, it can easily be embedded or shared on other sites such as Facebook.
As Sally Church noted on Pharma Strategy Blog when discussing Antibody Drug Conjugates, video lends itself well to physician education and discussing complex mechanisms of action. However, she notes that pharma and biotech companies still “have a long way to go yet in terms of how they can help improve learning about the science behind new cancer treatments.”
To enhance our video capabilities, Pieter Droppert recently spent 5 days on the Columbia Journalism School Digital Media Boot Camp.
He wrote a daily report about his experiences on Biotech Strategy Blog.
- Day 1 – camera set-up and technique
- Day 2 - lighting & sound
- Day 3 - field shooting
- Day 4 - video editing and Final Cut Pro
- Day 5 – production of final video
The boot camp took participants through the production of a video project from camera technique, composition, framing, lighting to shooting video and editing in Final Cut Pro.
You can watch Pieter’s course project on the smoking ban in New York City parks below:
While at Quintiles, Pieter Droppert was a lead CRA and European project manager for risedronate clinical trials, and he has since maintained an interest in osteoporosis new product development.
On the Biotech Strategy Blog, he discusses a recent review published in Nature Reviews Drug Discovery on the emerging treatments in development for osteoporosis. He comments on some of the barriers to market entry that companies will increasingly face such as pressure not to do placebo-controlled trials with high fracture-risk subjects.
For further commentary and insight on the osteoporosis market, read the full post on Biotech Strategy Blog.
iPad innovation – now you can use it to view medical images and diagnose patients
February 7th, 2011
Daedalus
All of us in the biotechnology or pharmaceutical industries with an interest in technology and how it can be leveraged to bring new drugs to market, received notice last Friday that the iPad is likely to have an impact on our industry.
The FDA announced their first approval of an app that allows physicians to view medical images on their iPhone and iPads, and use it to make a diagnosis.
If you own an iPad or aspire to own one, you can read more about this exciting new development on the Biotech Strategy Blog.
PI3K inhibition overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer
January 18th, 2011
Daedalus
Published by Sally Church on Pharma Strategy Blog